3 biotech stocks with potential for further growth

July is the month of barbecues and holidays. For many people, it is a time of relaxation and time off from difficult decisions, including investment ones. But analysts think they have a solution for those investors who want to invest in biotech stocks with minimal deliberation.

Three major biotech companies, Eli Lilly, Regeneron Pharmaceuticals and Vertex Pharmaceuticals, dominate the market with their innovative drugs and strong research focus. According to analysts, each of these companies represents a unique investment opportunity with a wide range of growth catalysts that can deliver attractive returns over the long term.

Eli Lilly $LLY-2.7%


Eli Lilly

$915.84 -$25.76 -2.74%

David Jagielski considers Eli Lilly one of the best growth stocks on the market. This pharmaceutical company offers a broad portfolio of growth catalysts, including the diabetes drug Mounjaro and the recently approved weight-loss drug Zepbound. Together, these products brought in $2.3 billion in the first three months of the year.

Mounjaro is now the company's best-selling drug, surpassing even Trulicity. Eli Lilly is also developing other promising drugs such as Retatrutide for obesity and Alzheimer's treatment donanemab. With the stock having nearly doubled in the past year, and with growth expected to continue, Eli Lilly is an attractive option for long-term investors.

The company has a market capitalization of $886 billion and its stock is trading in today's range of $920.77 to $935.00. With a gross margin of 80.16% and a dividend yield of 0.52%, Eli Lilly appears to be a stable and promising investment option.

Regeneron Pharmaceuticals $REGN-1.3%

$1,080.78 -$14.21 -1.30%

Junior Bakiny's Prosper highlights Regeneron Pharmaceuticals' ability to generate above-average revenues through innovative therapeutic approaches. The company rose to prominence during the COVID-19 pandemic through the development and commercialization of an anti-COVID-19 antibody, which contributed significantly to its revenues.

Key products include Dupixent for the treatment of eczema and Eylea for the wet form of age-related macular degeneration. Regeneron is also investing in innovation, including gene therapy for genetic deafness, indicating its long-term growth potential.

Vertex Pharmaceuticals $VRTX-1.7%

$480.83 -$8.15 -1.67%

Keith Speights sees Vertex Pharmaceuticals as a solid investment opportunity due to its strong portfolio of cystic fibrosis (CF) therapies. Trikafta/Kaftrio, the company's drug, dominates the CF market, making it a major player in the field. Vertex is also expanding its portfolio with new products, including Casgeva, the first CRISPR gene-editing drug approved for sickle cell anemia and beta-thalassemia.

The company has a market capitalization of $125 billion. With a gross margin of 86.85% and no dividend yield, Vertex Pharmaceuticals is a strong player in the biotech market with hopes for continued growth and innovation.

These three biotech companies offer investors a broad portfolio of growth catalysts and stable revenue streams, making them attractive long-term holdings. Their ability to innovate and adapt in the marketplace gives them significant advantages in the dynamic environment of the biotechnology industry.

Disclaimer: There is a lot of inspiration to be found on Bulios, but stock selection and portfolio construction is entirely up to you, so always conduct thorough self-analysis.

Source: Yahoo Finance, CNBC.

Read the full article for free?
Go ahead 👇

Do you have an account? Then log in . Or create a new one .

No comments yet
Timeline Tracker Overview